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Memory T cells (TM cells) are critical for the immune response against recurring infections. Their longevity and tissue localization allows TM cells to maintain effective 
immunity against bacteria, protozoa and viruses1–3. A key charac-
teristic of both CD8+ and CD4+ TM cells is their capacity to produce 
substantial amounts of effector molecules within a few hours upon 
reinfection4–6. This rapid responsiveness limits pathogen spread 
and recruits innate immune cells to the site of infection7,8. The swift 
recall response by TM cells is supported by changes in chromatin 
structure and epigenetic modifications that increase transcription 
rates of genes encoding effector molecules9–11. As a result, mRNAs 
encoding proinflammatory cytokines such as interferon (IFN)-γ 
are higher in human and mouse TM cells than in naive T cells12–14. 
Pre-formed Ifng and tumor necrosis factor (Tnf) mRNA is criti-
cal for instantaneous protein production upon T cell activation15. 
Such pre-formed mRNA is advantageous for recall responses, as 
cytokines can be rapidly produced without initiating transcription. 
However, chronic cytokine production can elicit severe immuno-
pathology16,17. Because pre-formed mRNA is ready to be trans-
lated, it is critical that protein production is tightly regulated and 
strictly confined to reactivated TM cells. How chronic and undesired 
cytokine production from pre-formed mRNA is prevented in TM 
cells is unknown.
Post-transcriptional regulation is a critical modulator of protein 
production, acting by regulating mRNA stability, changing mRNA 
localization and inhibiting protein translation. RNA-binding pro-
teins (RBPs) and noncoding RNAs such as microRNAs mediate 
these processes by binding to sequences located in the 3′ UTR of 
the mRNA18–20. For instance, global downregulation of microRNAs 
during T cell activation promotes the acquisition of effector func-
tions21,22. Whereas microRNA activity is primarily associated with 
keeping T cells quiescent, RBPs can directly promote T cell effec-
tor responses. The activity of RBPs can be regulated by different 
post-translational modifications23,24. RBPs bind to secondary RNA 
structures, such as the constitutive decay element25, or to short 
single-stranded sequences, such as GU-rich or AU-rich elements 
(AREs)26. The 3′ UTR of many cytokines, including Ifng, Tnf and 
interleukin-2 (Il2), contain AREs that consist of one or several 
AUUUA pentamers27. RBP binding to AREs is thought to primarily 
modulate mRNA stability, which is supported by the observation 
that many ARE-bearing transcripts display a short mRNA half-life28.
We found here that rapid mRNA turnover was not sufficient to 
avoid chronic protein production in TM cells. Rather, AREs were 
critical for blocking translation of pre-formed mRNA, a process that 
was mediated by the ARE-binding protein ZFP36L2. Thus, TM cells 
can contain deployment-ready mRNA for rapid recall responses 
because the recruitment of pre-formed cytokine mRNA to ribo-
somes is prevented in the absence of infection.
Results
The 3′ UTR of Ifng determines protein expression levels in 
TM cells. We first examined whether the Ifng 3′ UTR regulated 
protein production in TM cells. We fused the mouse Ifng 3′ UTR 
to a GFP reporter gene (hereafter GFP-Ifng3′ UTR) under the con-
trol of the mouse Pgk1 promoter. We retrovirally transduced OTI 
T cell antigen receptor (TCR) transgenic CD8+ T cells expressing 
the congenic marker CD45.1 with GFP-Ifng3′ UTR or with GFP that 
lacked a 3′ UTR (hereafter GFPcontrol). The next day, 1,000 sorted 
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GFP-Ifng3′ UTR OTI or GFPcontrol OTI cells were transferred into 
naive C57BL/6J/CD45.2 recipient mice, followed by infection with 
the intracellular bacterium Listeria monocytogenes genetically engi-
neered to express ovalbumin (LM-OVA)29 the next day. We found 
identical percentages of GFP-Ifng3′ UTR and GFPcontrol OTI cells in 
the blood of recipient mice at all time points measured (Fig. 1a). 
The GFPcontrol OTI cells expressed constant levels of GFP throughout 
the infection as determined by the GFP mean fluorescence intensity 
(GFP MFI; Supplementary Fig. 1a). In contrast, the GFP MFI in GFP-
Ifng3′ UTR OTI cells increased at day 9 postinfection and dropped 
at day 13, when the infection was resolved (Supplementary Fig. 1a). 
At day 35 postinfection, the GFP MFI was about sixfold lower 
for GFP-Ifng3′ UTR OTI cells than for GFPcontrol OTI cells isolated 
from blood, liver and spleen (Fig. 1b,c and Supplementary Fig. 1b). 
Reactivation of OTI cells isolated at day 35 postinfection with 
the OVA257–264 peptide did not alter the MFI of GFPcontrol OTI cells 
(P = 0.4), but it increased the expression of GFP-Ifng3′ UTR com-
pared to nonactivated cells (P = 0.01, Fig. 1b,c).
Spleen-derived GFPcontrol CD4+ and CD8+ T cells from C57BL/6J 
mice showed high GFP MFI when cultured in interleukin-7 for sev-
eral days in the absence of antigen (hereafter ‘resting’), and reac-
tivation for 4 h with phorbol 12-myristate 13-acetate (PMA) plus 
ionomycin did not alter the GFP MFI. In contrast, GFP-Ifng3′ UTR 
T cells had low GFP MFI when resting, and reactivation led to GFP 
induction (Supplementary Fig. 1c–f). The MFI of endogenous IFN-γ 
protein was equal in GFP+ and GFP– T cells (Supplementary Fig. 1g), 
indicating that the factors that control protein production were not 
limiting. Similar results were obtained using the minimal mouse 
Ifng promoter30 (Supplementary Fig. 1h), suggesting that the regula-
tory capacity of the Ifng 3′ UTR is independent of a specific pro-
moter. Combined, these data imply that the Ifng 3′ UTR controls 
protein production in TM cells.
Conserved AREs in the Ifng 3′ UTR determine protein expression 
in T cells. We next defined the regulatory region within the Ifng 3′ 
UTR using deletion mutants. Only reporter constructs containing 
the first 241 nucleotides of Ifng 3′ UTR reduced GFP MFI similarly 
to the GFP-Ifng3′ UTR reporter in resting OTI cells and maintained 
the induction upon 6 h reactivation with OVA257–264 peptide (Fig. 2a), 
indicating that this domain was essential in mediating protein 
expression. The mouse Ifng 3′ UTR contains six class I AREs, of 
which five are located within the first 241 nt (Fig. 2b). Mutating 
the ARE located outside of the 241-nt region of the Ifng 3′ UTR 
(GFP-IfngMUT6) did not alter the regulatory capacity of the Ifng 3′ 
UTR (Fig. 2c), while the combined site-directed mutation of all five 
AREs located within the proximal 241-nt region (GFP-IfngMUT1–5) 
completely abrogated its regulatory activity (Fig. 2c). Resting OTI 
cells transfected with GFP-IfngMUT1–5 had a GFP MFI similar to that 
of GFPcontrol, which did not increase upon activation with OVA257–264 
peptide (Fig. 2c).
Single or double mutants of the five AREs within the proximal 
241-nt region only marginally altered the GFP MFI in resting T cells 
compared with the GFP-Ifng3′ UTR, and activation with OVA257–264 
peptide resulted in an incomplete, but significant, increase of GFP 
MFI (Supplementary Fig. 2a,b). Mutating the first three AREs 
(GFP-IfngMUT1–3), clustered at position 74–98 nt, fully abrogated the 
induction of GFP MFI in OVA257–264-activated OTI cells, and this 
deletion only partially blocked protein expression in resting T cells 
compared to GFPcontrol and GFP-IfngMUT1–5 (Fig. 2d,e). Mutation of 
the AREs at position 137–141 nt and 192–196 nt (GFP-IfngMUT4 and 
GFP-IfngMUT5, respectively) was required to completely block pro-
tein production in resting T cells (Fig. 2d).
The ARE-containing region of the Ifng 3′ UTR is highly con-
served in human, mouse and many other mammals (Supplementary 
Fig. 2c). Human CD4+ and CD8+ T cells transduced with the 
human GFP-IFNG3′ UTR had lower GFP MFI than T cells trans-
duced with GFPcontrol (Fig. 2f and Supplementary Fig. 2d). As with 
mouse IfngMUT1–3, human GFP-IFNGMUT1–3 T cells showed higher 
GFP MFI than wild-type GFP-IFNG3′ UTR T cells, but 4 h reactiva-
tion with PMA plus ionomycin did not increase GFP MFI (Fig. 2f 
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Fig. 1 | The 3′ uTR of Ifng governs GFP expression in memory T cells in vivo. a, Blood samples of LM-OVA-infected C57BL/6 J/CD45.2 recipient mice 
were analyzed for the presence of CD45.1+ OTI cells expressing GFP-Ifng3′ UTR or GFPcontrol reporter (n =  10 per group; mean ±  s.d.). b,c, GFP MFI levels 
measured directly ex vivo in spleen-residing (b) and liver-residing (c) OTI cells 35 d after infection (unpaired Student t-test; n =  5 mice per group; 
mean ±  s.d.; **P <  0.005), showing representative GFP expression in memory OTI cells directly ex vivo (memory) and upon reactivation with OVA257–264 
peptide (+ OVA (6 h)). Numbers in plots depict the GFP MFI of the total population (top number) and the percentage of T cells within the upper gate that 
express high GFP levels (bottom number). Data shown are representative of 2 independently performed experiments.
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and Supplementary Fig. 2d). In contrast, human GFP-IFNGMUT1–5 
T cells expressed GFP MFI comparably to GFPcontrol T cells (Fig. 2f 
and Supplementary Fig. 2c). These findings indicate that the highly 
conserved proximal region of the IFNG 3′ UTR in humans and Ifng 
3′ UTR in mice blocks protein production in resting T cells through 
an ARE-dependent mechanism.
Deletion of Ifng 3′ UTR AREs causes chronic IFN-γ produc-
tion in TM cells. To investigate the effect of deleting AREs from the 
endogenous Ifng mRNA in TM cells, we crossed OTI mice with mice 
carrying a germline replacement of the ARE-containing region 
with a random sequence (hereafter IFN-γ -ARE-Del OTI mice)16. 
To compare the expansion kinetics and cytokine production of 
IFN-γ -ARE-Del OTI cells with wild-type OTI cells in response to 
LM-OVA infection, we transferred equal numbers (500 cells) of 
sorted naive CD62LhiCD44loIFN-γ -ARE-Del CD45.2 OTI cells and 
wild-type CD45.1 OTI cells into C57BL/6J CD45.1× CD45.2 recipi-
ent mice. This ensured an equivalent bacterial load and a similar 
cytokine milieu during the course of infection. One day after T cell 
transfer, recipient mice were infected with LM-OVA. We followed 
the OTI responses to LM-OVA infection by measuring the percent-
age of IFN-γ -ARE-Del and wild-type OTI cells within the CD8+  
T cell population in the blood. At days 6 and 9 postinfection, the 
percentage of IFN-γ -ARE-Del and wild-type OTI cells was simi-
lar. At day 13, when the infection was cleared, OTI cells contracted 
equally (Fig. 3a). At day 35 after LM-OVA infection, similar percent-
ages of OTI cells were found in blood, spleen, liver and bone mar-
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Fig. 2 | Au-rich elements within the Ifng 3′ uTR determine protein production in mouse and human T cells. a–e, OTI cells were transduced with 
deletion mutants containing the indicated ranges of nucleotides (a) or with ARE mutants of the full-length mouse Ifng 3′ UTR (c–e). b, Sequence of 
the mouse Ifng 3′ UTR. AREs are underlined. a,c, Representative GFP levels of resting OTI cells (gray histograms) and OTI cells after reactivation with 
OVA257–264 peptide for 6 h (black lines). d, GFP MFI of resting OTI cells transduced with the indicated ARE mutants. e, Fold increase of GFP MFI upon 
activation with OVA257–264 peptide compared to nonactivated GFP-expressing T cells. In d,e, data are presented as mean ±  s.d. of at least 3 independently 
performed experiments (one-way ANOVA with Dunnett’s multiple comparison to the control vector; n =  8 mice per group; *P <  0.005; **P <  0.0005; ns, 
not significant). (f) Human T cells were transduced with full-length human GFP-IFNG3′ UTR (WT) or with ARE mutants. Dot plots depict GFP MFI levels 
from resting T cells (top) or from T cells reactivated with PMA plus ionomycin (iono; bottom), with CD8+ T cells shown in black and CD4+ T cells in gray; 
APC, allophycocyanin. Data shown are representative of 4 individuals and of 3 independently performed experiments. Compiled data are depicted in 
Supplementary Fig. 2d.
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not shown). In addition, the percentage of CD44hiCD62LloCD127lo 
effector T (TEFF) cells, CD44hiCD62LloCD127hi effector memory T 
(TEM) cells and CD44hiCD62LhiCD127hi central memory T (TCM) 
cells, as well as the percentage of KLRG1hiCD127lo short-lived 
effector cells (SLEC) and KLRG1loCD127hi memory precursor cells 
(MPEC), was indistinguishable between IFN-γ -ARE-Del and wild-
type OTI cells (Fig. 3b and Supplementary Fig. 3a).
Despite the normal differentiation into TEFF and TM cells, blood-
derived IFN-γ -ARE-Del OTI cells isolated from CD45.1× CD45.2 
recipient mice on day 35 postinfection produced IFN-γ even in the 
absence of peptide restimulation, as defined by intracellular cyto-
kine staining after 3 h of incubation with brefeldin A (BFA) (Fig. 
3c). The IFN-γ production was also detected in spleen-, liver- and 
bone marrow–derived IFN-γ -ARE-Del OTI cells 35 d postinfection 
(Fig. 3c), as well as in spleen- and liver-derived IFN-γ -ARE-Del OTI 
cells 48 d postinfection (Supplementary Fig. 3b). In contrast, wild-
type OTI cells that were transferred into the same CD45.1× CD45.2 
recipient mice did not produce IFN-γ (Fig. 3c and Supplementary 
Fig. 3b). Wild-type and IFN-γ -ARE-Del T cells also did not produce 
TNF (Fig. 3c). At day 35 postinfection all liver and spleen-derived 
IFN-γ -ARE-Del T cells—TEFF cells, TEM cells, TCM cells, SLECs and 
MPECs—produced IFN-γ , as determined by the percentage and 
MFI of IFN-γ protein (Fig. 3d and Supplementary Fig. 3c,d).
The expression of Ifng mRNA was similar in sorted IFN-γ -ARE-
Del and wild-type OTI cells at day 35 postinfection (Fig. 3e), indi-
cating that IFN-γ production of IFN-γ -ARE-Del OTI cells did not 
correlate with increased mRNA expression. To determine whether 
this leaky IFN-γ production also occurs in other settings, we studied 
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Fig. 3 | Deletion of AREs in the Ifng 3′ uTR dysregulates protein production in TM cells. a, Percentage ±  s.d. of CD8+ OTI cells in blood drawn from LM-
OVA-infected mice at the indicated time points (n =  8 mice per group). b, Representative dot plots of CD44 versus CD62L expression (left) and of CD127 
versus KLRG1 expression (right) of wild-type OTI CD45.1 and IFN-γ -ARE-Del OTI CD45.2 cells 35 d after LM-OVA infection. Numbers in dot plots indicate 
percentage of OTI cells in corresponding gates. Compiled data are depicted in Supplementary Fig. 3a. FITC, fluorescein isothiocyanate; BV, brilliant violet; 
PerCP, peridinin-chlorophyll proteins; PE, phycoerythrin; Cy, cyanine. c, IFN-γ and TNF production measured in blood, spleen, liver and bone marrow (BM)-
derived TM cells after 3 h incubation with 1 μ g/ml BFA. Histograms represent wild-type OTI CD45.1 (gray histograms) and IFN-γ -ARE-Del OTI CD45.2 
(black lines) TM cells. Numbers depict percentage of IFN-γ + and TNF+ T cells. IFN-γ and TNF MFI of wild-type and IFN-γ -ARE-Del T cells was compared 
using an unpaired Student t-test (n =  4 mice per group; *P <  0.05; **P <  0.005; ***P <  0.0005). d, Percentage ±  s.d. of IFN-γ -producing T cells from spleen-
residing wild-type (gray square) and IFN-γ -ARE-Del (white square) CD44hiCD62LloCD127lo TEFF, CD44hiCD62LloCD127hi TEM, CD44hiCD62LhiCD127hi 
TCM, KLRG1hiCD127lo SLEC and KLRG1loCD127hi MPEC cells 35 d after LM-OVA infection (unpaired Student t-test; n =  4 mice per group; **P <  0.005; 
***P <  0.0005). e, Ifng mRNA expression, normalized to Rpl32 (L32), in sorted splenic wild-type or IFN-γ -ARE-Del OTI TM cells 35 d after LM-OVA 
infection (pooled from 4 mice). In a–e, data shown are representative of 2 independently performed experiments. f,g, IFN-γ protein (left) and mRNA levels 
(right) of sorted spleen-derived (f) and liver-derived (g) CD44hiCD8+ wild-type and IFN-γ -ARE-Del OTI cells. Representative dot plots of 4 mice. mRNA 
data ±  s.d. are pooled from 4 independently performed experiments. In e–g, unpaired Student t-test; ns, not significant.
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naturally occurring CD44hi memory-like T cells. Like infection-
induced TM cells, spleen-derived CD44hi sorted OTI cells mediate 
protection to LM-OVA infection by rapidly producing IFN-γ upon 
antigen exposure31. CD44hi OTI cells expressed more Ifng mRNA 
than naive CD44lo OTI cells (Supplementary Fig. 3e). Only CD44hi 
IFN-γ -ARE-Del cells produced IFN-γ ex vivo when cultured for 4 h 
in the absence of stimulation (Fig. 3f,g and Supplementary Fig. 3f,g). 
Yet the Ifng mRNA levels of IFN-γ -ARE-Del OTI cells were compa-
rable to those of wild-type CD44hi OTI cells (Fig. 3f,g). Again, the 
IFN-γ production was observed in spleen-derived CD44hiCD62Llo 
TEFF and TEM cells and in CD44hiCD62Lhi TCM cells from 
IFN-γ -ARE-Del mice (Supplementary Fig. 3f,g), but not from wild-
type mice, whereas T cells from both genetic backgrounds expressed 
identical Ifng mRNA levels (Supplementary Fig. 3h). Thus, the ARE 
region within the Ifng mRNA controls the production of IFN-γ in 
TM cells by post-transcriptional mechanisms.
The ARE-binding protein ZFP36L2 interacts with Ifng mRNA. To 
investigate how AREs prevent the production of IFN-γ in TM cells, 
we pulled down the ARE-binding proteins from cytoplasmic cell 
lysates of in vitro expanded, resting primary human T cells using 
the streptavidin-binding RNA aptamer 4xS1m32, which expresses 
the 189-nt ARE region of the human IFNG 3′ UTR, and analyzed 
them by mass spectrometry. To reduce false positive results, we 
included the empty 4xS1m RNA aptamer lacking the ARE region as 
a control (4xS1m-empty) and performed the purifications in tripli-
cate. ARE binding was scored positive when a protein was identified 
in all three samples. This analysis identified 83 proteins that bound 
IFNG-4xS1m but not 4xS1m-empty. Fifty-seven proteins were sig-
nificantly enriched (Student t-test, false discovery rate (FDR) = 0.05, 
scatter S0 = 0.4) upon purification with the IFNG-4xS1m construct 
(Fig. 4a). To validate ARE-specific binding, we performed a second 
purification that included the human IFNGMUT1–5 variant, IFNGMUT1–
5-4xS1m. Eighty out of the 83 proteins found in the first purification 
were also detected in the second purification. Of these, we identified 
two proteins, ZFP36L1 and ZFP36L2, that interacted with IFNG-
4xS1m but not with IFNGMUT1–5-4xS1m or with 4xS1m-empty 
(Fig. 4a and Supplementary Fig. 4a–d).
ZFP36L1 (TIS11B) and ZFP36L2 (TIS11D) are ZFP36 (tristet-
raprolin or TTP)-family proteins, which bind AREs33,34. ZFP36 
induces cytokine-encoding mRNA degradation in T cells, and 
ZFP36-deficient mice develop severe autoimmunity due to excessive 
cytokine production35,36. We detected more Zfp36l2 than Zfp36l1 
mRNA in spleen-derived CD44hiCD8+ T cells, along with more 
ZFP36L2 than ZFP36L1 protein (Fig. 4b,c). Furthermore, ZFP36L2 
protein expression was comparable in naive T cells, in CD44hi TM 
cells and in TM cells reactivated with PMA plus ionomycin, while 
ZFP36L1 was only detectable upon T cell activation (Supplementary 
Fig. 4e). Native RNA immunoprecipitation (i.e., immunoprecipita-
tion without cross-linking) showed that Ifng mRNA was enriched 
in ZFP36L2 pulldowns from resting T cells, but not from resting 
IFN-γ -ARE-Del T cells (Fig. 4d). Thus, ZFP36L2 interacts specifi-
cally with the ARE region of the Ifng 3′ UTR.
ZFP36L2 represses IFN-γ production independently of mRNA 
stability. Next we used mice with a conditional deletion of ZFP36L2 
in the T cell lineage37 to assess the role of ZFP36L2 deficiency in 
CD44hi memory-like T cells. CD4-Cre Zfp36l2flox/flox mice (hereaf-
ter Zfp36l2cKO) had a similar percentage of CD8+ and CD4+ TEFF, 
TEM and TCM cell subsets in the spleen to their wild-type littermates 
(Supplementary Fig. 5a). However, spleen-derived CD44hi CD8+ 
and CD4+ T cells from Zfp36l2cKO mice, but not from wild-type lit-
termates, produced IFN-γ in the absence of stimulation (Fig. 5a,b), 
whereas Ifng mRNA amounts were comparable to those in wild-
type CD44hi T cells (Fig. 5a,b).
We next tested whether loss of ZFP36L2 also affected the GFP 
reporter constructs. We transduced wild-type and Zfp36l2cKO T cells 
with GFPcontrol, GFP-Ifng3′ UTR or GFP-IfngMUT1–5. The GFP MFI of 















































































































Fig. 4 | The RNA-binding protein ZFP36L2 binds Ifng mRNA. a, Volcano 
plot of RBPs quantified by mass spectrometry from human resting T cell 
lysates pulled down with in vitro transcribed 4xS1m mRNA containing 
the 189-nt ARE-region of the human IFNG 3′ UTR (4xS1m-IFNG) and the 
empty 4xS1m mRNA control (4xS1m-empty). Only proteins identified 
in all three replicates were considered putative ARE binders. Gray dots 
represent proteins that were significantly enriched in the presence of the 
IFNG 3′ UTR; white dots represent proteins enriched in 4xS1m-empty 
(two-sided t-test; FDR =  0.05, S0 =  0.4). Heat map depicts Z-scored log2 
of the label-free quantification values of ZFP36L1 and ZFP36L2 in all three 
replicates. b,c, mRNA (b) and protein (c) expression of ZFP36L1 and 
ZFP36L2 in CD44hiCD8+ T cells. For the immunoblot, erythroblasts (EBL) 
were used as a positive control54. d, Binding of ZFP36L2 to Ifng mRNA 
in resting wild-type and IFN-γ -ARE-Del OTI cells was analyzed by RNA-
immunoprecipitation (RNA-IP). IgG isotype was used as a control. Top: 
ZFP36L2 protein expression upon RNA-IP, detected with a pan-ZFP36 
antibody at ±  55 kDa (specific size of ZFP36L2). Bottom: data are pooled 
from 3 independently performed experiments. In b,d, data are presented 
as mean ±  s.d. (unpaired Student t-test; n =  4 mice per group; ns, not 
significant; *P <  0.05; ****P <  0.0001).
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wild-type and Zfp36l2cKO T cells (Fig. 5c,d). In contrast, GFP MFI 
was substantially increased in GFP-Ifng3′ UTR CD8+ T cells and in 
CD4+ Zfp36l2cKO T cells compared to wild-type T cells (Fig. 5c,d), 
indicating that ZFP36L2 represses IFN-γ production in T cells.
AREs are primarily associated with the regulation of mRNA sta-
bility16,17,35,38. The overall amount of mRNA depends on the tran-
scription rate and the rate of mRNA decay. We measured the rate 
of mRNA decay by treating resting OTI cells with the polymerase 
II transcription inhibitor actinomycin D (ActD). Ifng mRNA had 
a longer half-life in IFN-γ -ARE-Del OTI cells (t1/2 > 120 min) than 
in wild-type OTI cells (t1/2 ~30 min; Fig. 5e). The half-life of Ifng 
dropped to t1/2 ~60 min in sorted CD44hi IFN-γ -ARE-Del OTI 
cells, compared to t1/2 ~30 min in wild-type OTI cells (Fig. 5f). 
Following 120 min of ActD treatment, the decay of Ifng mRNA 
in IFN-γ -ARE-Del OTI cells was similar to that in wild-type OTI 
cells (Fig. 5f), indicating that the Ifng mRNA stability ex vivo is 
substantially lower than in vitro. This was not the case for other 
transcripts, as Tnf remained unstable and 18S remained stable 
(Supplementary Fig. 5b–e). Similar data were obtained using 
polyclonal CD4+ and CD8+CD44hi T cells from IFN-γ -ARE-DEL mice 
(Fig. 5g and Supplementary Fig. 5f). The rate of Ifng mRNA decay in 
Zfp36l2cKO CD4+ and CD8+ CD44hi T cells was comparable to that in 
IFN-γ -ARE-DEL T cells (Fig. 5h and Supplementary Fig. 5g), indi-
cating the ARE-independent degradation of Ifng mRNA did not 
require ZFP36L2. In addition, the amount of miR-29a and miR-29b, 
which can affect Ifng mRNA expression39,40, and the expression of 
Tbx21 and Eomes mRNA, which encode the transcription factors 
T-bet and eomesodermin, were similar in IFN-γ -ARE-Del and 
wild-type CD44hi TM cells (Supplementary Fig. 5h), suggesting that 
the expression of these factors was not influenced by IFN-γ -ARE-
Del-mediated alterations in TM cells. As such, Ifng AREs determine 
Ifng mRNA stability depending on the activation status of T cells, 
and they do so in a ZFP36L2-independent manner.
ZFP36L2 blocks the association of Ifng mRNA to ribosomes in 
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Fig. 5 | The ARE-binding protein ZFP36L2 represses IFN-γ production in TM cells. a,b, IFN-γ production of sorted splenic CD44hiCD8+ (a) and 
CD44hiCD4+ (b) T cells from Zfp36l2cKO mice compared to wild-type littermates after 3 h incubation with BFA (top; n =  6 mice per group) and  
IFN-γ -ARE-Del mice compared to C57BL/6 J wild-type mice (bottom; n =  5 mice per group). Left: representative dot plot. Middle: compiled data 
(mean ±  s.d.) depicting the fold increase of IFN-γ production compared to wild-type mice. Right: Ifng mRNA expression levels ±  s.d. c, T cells from 
Zfp36l2cKO mice and wild-type littermates were retrovirally transduced with GFP-Ifng3′ UTR, GFPMUT1–5 or GFPcontrol. Left: dot plots represent GFP expression 
of CD8+ T cells. Right: GFP geometric (Geo)-MFI of CD8+ and CD4+ T cells that were rested in recombinant mouse interleukin-7 for 5 d (n =  3 mice per 
group; mean ±  s.d.). FSC, forward scatter. d,e, Ifng mRNA levels of in vitro resting OTI cells (d) or ex vivo sorted CD44hiCD8+ OTI cells (e) after treatment 
with 1 μ g/ml ActD for the indicated times. Results ±  s.d. are pooled from 4 independently performed experiments (n =  4 mice per group). f,g, Ifng mRNA 
stability was assessed upon ActD treatment of CD44hiCD8+ T cells or CD44hiCD4+ T cells from IFN-γ -ARE-Del (f; n =  5 mice per group) or Zfp36l2cKO  
(g; n =  3 mice per group) mice and their respective wild-type controls. Results ±  s.d. are pooled from 2 independently performed experiments. For 
individual data points, see Supplementary Fig. 5f,g. In a–h, unpaired Student t-test; ns, not significant; *P <  0.05; **P <  0.005.
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and translation of Ifng mRNA in TM cells. We treated spleen-derived 
IFN-γ -ARE-Del CD44hi memory-like T cells with ActD or the 
translation inhibitor cycloheximide (CHX) and measured IFN-γ 
production in the absence of stimulation. Blocking transcription 
with ActD did not interfere with IFN-γ production in IFN-γ -ARE-
Del CD44hi T cells (Fig. 6a,b). We did not detect TNF production in 
these cells, and cell viability and the surface markers CD8 and CD44 
were unaltered (Supplementary Fig. 6a). In contrast, treatment with 
CHX, which inhibits protein translation, blocked the production of 
IFN-γ in IFN-γ -ARE-Del CD44hi T cells compared to ActD-treated 
cells (Fig. 6a,b), indicating that the IFN-γ production depends on 
translation and that the pre-formed Ifng mRNA serves as template 
for protein production in IFN-γ -ARE-Del CD44hi TM cells.
To test whether AREs impair the translation of pre-formed Ifng 
mRNA, we measured the association of Ifng mRNA with ribosomes 
in spleen-derived IFN-γ -ARE-Del or wild-type CD44hi T cells. The 
heavy fraction of cytosolic extracts was pelleted by sucrose cushion 
centrifugation to enrich for ribosomes41. As a control, half of the 
each cytosolic extract was treated with 20 mM EDTA, which dis-
sociates ribosomal and ribosome-associated proteins from mRNA41 
(Supplementary Fig. 6b). mRNA levels measured from this control 
sample included residual binding of Ifng mRNA to ribosomes and 
unbound Ifng mRNA, and were subtracted from those of the pellets 
of EDTA-untreated sucrose cushions. Only the Ifng mRNA from 
IFN-γ -ARE-Del CD44hi T cells, but not from wild-type CD44hi  
T cells, associated with ribosomes (Fig. 6c). The association of con-
trol mRNAs Tnf and 18S was comparable between wild-type and 
IFN-γ -ARE-Del CD44hi T cells (Supplementary Fig. 6c,d). Notably, 
the Ifng mRNA from CD44hiCD4+ and CD44hiCD8+ Zfp36l2cKO  
T cells also associated with ribosomes (Fig. 6d,e), indicating that 
the recruitment of Ifng mRNA to the ribosome depended at least in 
part on ZFP36L2. Thus, AREs within the Ifng mRNA and ZFP36L2 
suppress the translation of IFN-γ protein from pre-existing mRNA 
in TM cells.
ZFP36L2 binds to pre-formed mRNA in memory T cells. To 
determine whether ZFP36L2 blocks the translation of other ARE-
containing mRNAs that are rapidly translated in TM cells upon 
activation, we sorted spleen-derived CD44hi memory-like OTI 
cells and performed mass spectrometry on untreated cells and on 
T cells activated for 2 h with OVA257–264 peptide. Of the 5,490 identi-
fied proteins, 54 significantly altered their expression profile upon 
T cell activation (Student t-test, FDR = 0.05, S0 = 0.4; Fig. 7a and 
Supplementary Fig. 7a). Seventeen proteins were significantly less 
abundant in stimulated T cells, including CD62L (Sell; Fig. 7a), 
which is rapidly downregulated upon T cell activation. Conversely, 
37 proteins were significantly induced in stimulated CD44hi OTI 
cells, including the early activation marker CD69 and the proin-
flammatory cytokines IFN-γ , TNF and interleukin-2 (Fig. 7a). Of 
note, 32 of these 37 proteins were generated from ARE-containing 
mRNAs (Fig. 7a and Supplementary Fig. 7a).
We next determined the mRNA levels of these rapidly induced 
proteins in TM cells. Fifty-two out of the 54 proteins that altered their 
expression profile upon activation of CD44hi OTI cells were anno-
tated in TEM and TCM cells specific for the lymphochoriomeningitis 
virus (LCMV)42. The mRNAs for the 17 proteins that were enriched 
in the CD44hi OTI cells were also expressed in LCMV-specific TEM 
and TCM cells (Fig. 7b and Supplementary Fig. 7b). The mRNAs of 
the 35 proteins that were rapidly induced in CD44hi OTI cells greatly 




































































































































































































































Fig. 6 | The interaction between AREs and ZFP36L2 blocks ribosome recruitment of pre-formed Ifng mRNA. a, Representative IFN-γ and TNF production 
of sorted CD44hiCD8+ memory-like IFN-γ -ARE-Del (top) and wild-type (bottom) OTI cells after 4 h incubation with BFA alone (left) or with 1 μ g/ml  
ActD (middle) or 10 μ g/ml CHX (right). b, Graphs depict percentage (mean ±  s.d. of 4 independently performed experiments) of IFN-γ -producing 
CD44hiCD8+ wild-type or IFN-γ -ARE-Del OTI cells incubated with or without ActD (left) or CHX (right) for the entire culture period of 4 h or for the last 
2 or 1 h. c–e, Ifng mRNA levels of cytosolic fractions from CD44hiCD8+ wild-type or IFN-γ -ARE-Del OTI cells (c), CD44hiCD8+ T cells (d) or CD44hiCD4+ 
T cells (e) from Zfp36l2cKO or wild-type littermates. Left: mRNA input before fractionation; right: mRNA measured in the ribosome-enriched fraction after 
centrifugation through a sucrose cushion. Ribosome binding was determined by comparing the mRNA levels from untreated cytosolic fractions with those 
of EDTA-treated fractions. Results (mean ±  s.d.) are pooled from 3 (c; n =  3–6 mice) or 2 (d,e; n =  3 mice) independently performed experiments (unpaired 
Student t-test; ns, not significant; *P <  0.05).
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Fig. 7b). LCMV-specific TEM and TCM cells expressed the mRNAs 
for 29 of the 35 (82.9%) rapidly generated proteins (Fig. 7b  
and Supplementary Fig. 7b). For 22 of these 35 proteins (62.9%), 
the peptide abundance was below detection limit in nonactivated 
CD44hi T cells (Supplementary Fig. 7a), indicating that these 22 
mRNAs are putatively blocked from translation in TM cells.
ZFP36L2 binds to ARE-containing mRNA with a tandem zinc 
finger43 that requires two AREs for interaction. Of the 35 rapidly 
induced proteins, 26 ARE-containing transcripts included at least 
2 AREs (defined as AUUUA) within the 3′ UTR (Supplementary 
Table 1). We focused on 11 putative target genes that fulfilled the fol-
lowing criteria: they contained two AREs in most of their transcript 
variants (Supplementary Table 1) and they expressed pre-formed 
mRNA in TM cells (Supplementary Fig. 7b). We measured ZFP36L2 
binding to these endogenously expressed mRNAs using native RNA-
immunoprecipitation in resting OTI cells. Of the 11 tested mRNAs, 
6 mRNAs were significantly enriched in resting T cells compared to 
the immunoglobulin G (IgG) control pulldown: Ifng, Tnf, Irf4, Junb, 
Zfp36l1 and Pim1 (Fig. 7c). This indicates that ZFP36L2 targets sev-
eral ARE-containing pre-formed mRNAs TM cells.
ZFP36L2 rapidly releases pre-formed mRNA upon activation. 
Because pre-formed mRNA drives rapid cytokine production upon 
T cell activation15, we tested whether T cell activation supports the 
release of pre-formed mRNA from ZFP36L2. As determined by 
RNA-immunoprecipitation, ZFP36L2 binding to Ifng mRNA was 
significantly reduced in OTI cells reactivated with OVA257–264 for 2 h 
compared to nonactivated, resting OTI cells (Fig. 7d). Of note, loss of 
mRNA binding upon reactivation coincided with rapid downregu-
lation of Zfp36l2 mRNA, but ZFP36L2 protein remained unaltered 
(Supplementary Fig. 7d). ZFP36L2 also rapidly dissociated from 
Tnf and Pim1 mRNA upon T cell activation, while its binding to 
Irf4, Junb and Zfp36l1 mRNA did not change compared to that in 
nonactivated T cells (Fig. 7d). Peptides for IFN-γ , TNF and Pim1 
were below detection limit in nonactivated CD44hi T cells in the pro-
teomics analysis (Supplementary Fig. 7a), further pointing to a block 
of mRNA translation. Tnf mRNA was significantly enriched in the 
ribosome-enriched fraction of Zfp36l2cKO CD8+ and CD4+CD44hi  
T cells compared to wild-type T cells (Fig. 7e), and TNF production 
was found in CD8+ and CD4+CD44hi T cells in the absence of stim-
ulation (Fig. 7f). These observations thus show that ZFP36L2 sup-
presses the translation of several target mRNAs in memory T cells.
Discussion
Here we found that the translation of pre-formed Ifng mRNA was 
actively repressed in TM cells. All five highly conserved AREs of 
the Ifng 3′ UTR contributed to the translational block, which may 
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Fig. 7 | ZFP36L2 blocks translation of pre-formed mRNA from rapidly generated effector molecules. a, Volcano plot of proteins quantified by mass 
spectrometry from splenic CD44hiCD8+ OTI cells that were cultured for 2 h with or without 100 nM of OVA257–264 peptide in the presence of 1 μ g/ml BFA 
(n =  3; two-sided t-test; FDR =  0.05, S0 =  0.4). b, mRNA expression of LCMV-specific spleen-derived TEM and TCM cells from ref. 42. Graphs display log2-
normalized counts of reads per million mapped reads (RPM) for proteins in a whose expression was significantly downregulated (left) or upregulated 
(right) upon T cell activation. In a,b, red dots depict proteins that are encoded by ARE-containing transcripts. c,d, ZFP36L2 RNA-immunoprecipitation 
of resting OTI cells compared to anti-IgG control RNA-immunoprecipitation (c) or compared to RNA-immunoprecipitation from cells reactivated for 
2 h with 100 nM OVA257–264 peptide (values from anti-IgG control RNA-immunoprecipitation were subtracted from each value) (d). Data are presented 
as mean ±  s.d. of 3 or 4 mice and pooled from 3 independently performed experiments. e,f, CD44hiCD8+ and CD4+ T cells were sorted from Zfp36l2cKO 
or wild-type littermates. e, Ribosome-bound Tnf mRNA measured by real-time PCR following centrifugation through a sucrose cushion. Graphs display 
mRNA expression levels ±  s.d relative to paired EDTA-treated control samples (n =  3). f, Spontaneous TNF protein production depicted as fold increase 
compared to that of wild-type mice (n =  6; mean ±  s.d). Results are pooled from 2 independently performed experiments. In c–f, unpaired Student t-test; 
*P <  0.05; **P <  0.005; ***P <  0.0005).
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polymorphisms. The ARE-binding protein ZFP36L2 mediated the 
translational silencing of pre-formed mRNA in TM cells. Germline 
deletion of the entire ARE-containing region and ZFP36L2 defi-
ciency in TM cells caused aberrant recruitment of pre-formed Ifng 
mRNA to ribosomes and led to IFN-γ protein production in the 
absence of activation. ZFP36L2 not only controlled the translation 
of Ifng, but also of Tnf and Pim1 mRNAs, encoding other rapidly 
induced proteins. Thus, the ARE-dependent inhibition of transla-
tion keeps TM cells silent in the absence of infection.
TM cells continuously receive tonic signals through cytokines 
and/or through their TCR that support their maintenance44–46. 
Tonic signaling drives the constitutive expression of unstable cyto-
kine mRNA47. We postulate that the active suppression of cytokine 
production is required to maintain TM cells silent in the absence of 
the infection. Whether tonic signaling also controls the function 
of ZFP36L2 is yet to be determined. Once TM cells become reacti-
vated, pre-formed mRNA is rapidly disengaged by ZFP36L2, allow-
ing the immediate production of protein. Because the expression of 
ZFP36L2 protein was not altered, ZFP36L2 could remain ready for 
rapid re-engagement, target other mRNAs, or exert different func-
tions in stimulated T cells.
ZFP36L1 mRNA and protein expression was lower in 
TM cells than that of ZFP36L2, and the contribution of ZFP36L1 
to the blockade of translation in TM cells may therefore be limited. 
However, because the binding of ZFP36L2 to mRNA is rapidly lost 
upon activation, ARE-mediated regulation may be highly versatile 
and dependent on the context. It is therefore conceivable that ZFP36 
and ZFP36L1 drive post-transcriptional events at other stages of 
T cell differentiation or activation. This also may hold true for other 
RBPs, such as TIA, which limits excessive TNF production through 
a translational block in lipopolysaccharide-stimulated macro-
phages48. Similar regulatory mechanisms may also occur in T cells, 
depending on the activation status.
The biological relevance of ARE-mediated cytokine production 
was highlighted by the germline deletion of AREs in the Ifng 3′ UTR 
or the Tnf 3′ UTR, which lead to chronic cytokine production and 
consequentially to autoimmune disease in mice16,17. Sixteen per-
cent of human protein-coding genes are thought to contain AREs49. 
Cytokine and chemokine mRNA transcripts are highly enriched 
for these sequences20,26, pointing to a specific role of AREs in the 
effector function of T cells. Also, the rapidly responding NK cells, 
NKT cells and myeloid cells constitutively express mRNAs encod-
ing effector molecules50,51. Conversely, self-reactive CD4+ T cells 
maintain their anergic phenotype by blocking the translation of 
cytokine mRNAs52. It is therefore tempting to speculate that the 
ARE-dependent translational repression described here is more 
broadly employed to regulate immune responses.
In conclusion, we identified a conserved mechanism that tightly 
regulates the translation of pre-formed cytokine mRNAs in CD8+ 
and CD4+ TM cells. Considering that tissue-resident CD8+ TM cells 
express even higher levels of mRNA encoding effector molecules than 
circulating TM cells53, our findings suggest that manipulation of ARE-
mediated post-transcriptional control may be exploited to rectify 
impaired T cell responses in tissues, as, for example, against tumors.
Methods
Methods, including statements of data availability and any asso-
ciated accession codes and references, are available at https://doi.
org/10.1038/s41590-018-0155-6.
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Methods
Mice and cell culture. Mice were obtained from Charles River or housed and 
bred in-house at the Netherlands Cancer Institute (NCI). IFN-γ -ARE-Del mice 
were generated as previously described16 and crossed to C57BL/6J.OTI T cell 
receptor (TCR) transgenic mice (OTI). Mice carrying a conditional allele of 
Zfp36l2 have been previously described37 and were crossed to mice in which the 
Cre recombinase is expressed under the control of mouse CD4 regulatory elements 
(Tg(CD4-cre)1Cwi) to obtain deletion specifically in T cells55. Experiments were 
performed in accordance with institutional and national guidelines and approved 
by the Experimental Animal Committee at the NCI.
Cells were cultured at 37 °C and 5% CO2 in IMDM (Gibco-BRL) containing 
8% FCS, 2 mM l-glutamine, penicillin and streptomycin, supplemented for mouse 
cells with 15 μ M 2-mercaptoethanol.
Cloning. Gene-specific 3′ UTRs were amplified from genomic DNA of a C57BL/6J 
mouse or from human genomic DNA (sequences upon request). The 3′ UTR 
variants were cloned into the ClaI site of pRETRO-SUPER GFP56 downstream of 
GFP. 189 nt of the human IFNG 3′ UTR were cloned into the pSP73-4xS1m32. The 
region containing the streptavidin binding sites was reversed using the two BglII 
sites, and the IFNG 3′ UTR was inserted into the 5′ end of the S1m motifs. Prior 
to in vitro transcription, the pSP73-4xS1m construct was linearized with NdeI. 
ARE mutants with a substitution of AUUUA sequence by AAAAA were obtained 
from GeneScript and subcloned into pRS-GFP or pSP73-4xS1m. Sequences were 
confirmed by sequence analysis.
T cell activation and retroviral transduction. 1.5 × 106 human PBMCs were 
activated in a 24-well plate for 40 h with plate-bound anti-CD3 and anti-CD28  
(1 μ g/ml each, eBioscience). Retroviral transduction was performed with 
Retronectin (Takara) as described57, and cells were maintained in culture in the 
presence of 20 ng/ml recombinant human interleukin-7 (PeproTech).
1 × 106 CD8-purified OTI T cells (Miltenyi CD8 isolation kit; 90–99% 
purity) were cultured for 20 h with 0.1 × 106 preseeded MEC.B7.SigOVA cells as 
described58. 3 × 106 C57BL/6 J splenocytes were activated for 48 h with concanavalin 
A (2 μ g/ml, Sigma) and recombinant mouse interleukin-7 (rmIL-7, 1 ng/ml, 
PeproTech), or with plate-bound anti-CD3 (2 μ g/ml, eBioscience) and soluble 
anti-CD28 (1 μ g/ml, Bioceros). Cells were harvested and retrovirally transduced 
as described59. T cells were maintained with 10 ng/ml rmIL-7 and reactivated with 
100 nM or 1 μ M OVA257–264, or with 10 ng/ml PMA and 1 μ M ionomycin (Sigma).
FACS-sorted CD8+ and CD4+CD44hi T cells were isolated from spleen or liver 
of 6- to 9-week-old mice. T cells were incubated for 4 h with brefeldin A (BFA), 
with or without 1 μ g/ml actinomycin D (ActD) or 10 μ g/ml cycloheximide  
(CHX) (Sigma).
Adoptive T cell transfer and L. monocytogenes–OVA infection. GFP-expressing 
OTI T cells were purified with Lympholyte M (Cedarlane) and FACS-sorted for 
GFP expression. Naive CD8+CD44loCD62Lhi WT and IFN-γ -ARE-Del OTI T cells 
were FACS-sorted from splenocytes. One thousand GFP+ OTI T cells, or 500 naive 
WT OTI CD45.1+ together with 500 naive IFN-γ -ARE-Del OTI CD45.2+ T cells, 
were adoptively transferred into recipient mice. The next day, mice were infected 
i.v. with 2.5 × 103 or 2.5 × 104 colony-forming units (CFU) of a L. monocytogenes 
strain expressing ovalbumin (LM-OVA). Peripheral blood was drawn to monitor 
T cell responses. 35–48 d after infection, spleen, liver and bone marrow cells were 
incubated with brefeldin A alone or reactivated for 6 h with 1 μ g/ml OVA257–264, and 
intracellular staining for IFN-γ was performed.
Flow cytometry. Mouse T cells were labeled for 20 min at 4 °C with anti-CD3 
(17A2), anti-CD4 (GK1.5), anti-CD8 (53-6.7), anti-CD45.1 (A20), anti-CD45.2 
(104), anti-Vβ 5.1–5.2 (MR9-4), anti-CD44 (IM7), anti-CD62L (MEL-14), anti-
CD127 (A7R34), anti-KLRG1 (MAFA), anti-IFN-γ (XMG1.2) and anti-TNF-α 
(MP6-XT22) (all eBioscience). Human T cells were labeled with anti-CD3 
(UCHT1, Beckman Coulter), anti-CD4 (SK3, BD Biosciences), anti-CD8 (SK1, 
BD Biosciences). Dead cells were excluded with 1 ng/ml TO-PRO-3 iodide 
(Sigma-Aldrich) or Near-IR (L10119, Life Technology). Intracellular cytokine 
staining was performed with the Cytofix/Cytoperm kit (BD Biosciences). Flow 
cytometry analysis was performed on LSR-II and LSR Fortessa (BD Biosciences). 
Data were analyzed with FlowJo software (Tree Star, version 7.6.5 and version 10). 
Representative flow cytometry gating strategies are found in Supplementary Fig. 8.
Quantitative PCR analysis. Total RNA was extracted using Trizol (Invitrogen) 
and cDNA was synthesized with SuperScript III (Invitrogen), unless otherwise 
specified. miRNAs were extracted from FACS-sorted CD8+CD44hi WT and  
IFN-γ -ARE-Del OTI T cells using the Total RNA Purification Plus Kit (Norgen 
Biotek), and cDNA was synthesized with the miScript II RT kit (Qiagen). RT-PCR 
was performed with triplicate reactions using SYBR Green on a StepOne Plus (both 
Applied Biosystems; for primer sequences, see ref. 58). Ct values were normalized to 
L32 levels and confirmed with 18S.
RNA immunoprecipitation and immunoblot. Cytoplasmic lysates of resting 
WT or IFN-γ -ARE-Del OTI T cells (250 × 106 cells per condition) were prepared 
using lysis buffer (10 mM HEPES, pH 7.0, 100 mM KCl, 5 mM MgCl2, 0.5% NP40) 
freshly supplemented with 1 mM DTT, 40 U/ml RNase OUT (both Invitrogen), 
0.4 mM vanadylribonucleoside complex RNase inhibitor (NEB) and 1% EDTA-free 
protease/phosphatase inhibitor cocktail (Thermo Scientific). Protein G Dynabeads 
(Thermo Scientific) were prepared as previously described60. The lysate was 
immunoprecipitated for 2 h at 4 °C with polyclonal rabbit anti-ZFP36L2 (ab70775) 
or a polyclonal rabbit IgG isotype control (ab27478, both Abcam). RNA was 
extracted directly from beads by using Trizol, and mRNA expression was measured 
by RT-PCR as described above. Specificity of the RNA-IP assay was tested by 
immunoblotting using a rat pan-ZFP36 antibody generated in the laboratory of 
M. Turner (unpublished data). This antibody is directed against the C terminus of 
ZFP36L1 and recognizes all three ZFP36 family members.
1 × 106 FACS-sorted CD8+CD44lo and CD8+CD44hi T cells were lysed according 
to standard procedures. Proteins were separated on a 10% SDS–PAGE gel and 
transferred onto a nitrocellulose membrane by iBlot (Thermo). Rabbit polyclonal 
anti-ZFP36L1 (ab42473), rabbit polyclonal anti-ZFP36L2 (ab70775, both Abcam), 
mouse monoclonal anti-RhoGDI (MAB9959, Abnova), mouse monoclonal 
anti-GAPDH (MAB374, Millipore), and a rat pan-ZFP36 antibody were used as 
primary antibodies, followed by goat anti-rabbit-HRP (4050-05), goat anti-mouse-
HRP (1031-05, both Southern Biotech) or goat anti-rat-HRP (31470, Invitrogen) 
secondary antibodies.
Sucrose cushion. 1 × 106 FACS-sorted CD8+ CD44hi WT or IFN-γ -ARE-Del 
OTI T cells were lysed in modified polysome buffer (20 mM Tris-HCl, pH 7.5, 
300 mM KCl, 5 mM MgCl2, 0.50% NP40) freshly supplemented with 2 mM DTT, 
40 U/ml RNase OUT and 10 μ g/ml CHX. Total cell lysate was treated or not 
with 20 mM EDTA, pH 8.0 (Invitrogen), layered over a 20% sucrose cushion 
and then centrifuged at 37,500 r.p.m. at 4 °C for 2 h in a SW60Ti swing-out rotor 
ultracentrifuge (Beckman Coulter). RNA was isolated from the pellet using a Total 
RNA Purification Plus Kit (Norgen Biotek), and mRNA expression levels were 
analyzed by RT-PCR. The distribution of transcripts within the ribosome-enriched 
fraction was calculated as fold increase relative to the amount of transcript 
precipitated in the corresponding EDTA-treated sample.
4xS1m RNA aptamer-protein pulldown. Human resting T cells were washed 
with PBS and the cell pellet was snap frozen in liquid nitrogen. The cell pellet was 
homogenized using 5-mm steel beads and a tissue lyser (Qiagen TissueLyser II) 
at 25 Hz for 15 s six times. The homogenate was then solubilized and precleared 
as previously described32. The 4xS1m RNA aptamers containing or not the 189 
nt of the human IFNG 3′ UTR were in vitro transcribed using the Ampliscribe 
T7-flash transcription kit (Epicentre) and coupled to Streptavidin Sepharose High 
Performance beads (GE Healthcare) as described32. RNA-coupled beads and cell 
lysate were incubated for 3.5 h at 4 °C under rotation in the presence of  
60 U RNasin (Ambion). For each pulldown, about 30 μ g in vitro transcribed 
RNA and 10 mg protein were used. RNA-bound proteins were eluted by adding 
1 μ g RNaseA (Thermo Scientific) and 100 μ l 100 mM Tris-HCl, pH 7.5 (Gibco-
Invitrogen). Proteins were reduced, alkylated and digested into peptides using 
trypsin. Peptides were desalted and concentrated using Empore-C18 StageTips61 
and eluted with 0.5% (v/v) acetic acid, 80% (v/v) acetonitrile. Sample volume was 
reduced by SpeedVac and supplemented with 2% acetonitrile, 0.1% TFA.
Proteomic analysis of OTI memory T cells. Triplicates of 2 × 106 FACS-sorted 
CD8+ CD44hi OTI T cells were incubated for 2 h in IMDM containing 5% FCS and 
1 μ g/ml BrfA with or without the presence of 100 nM OVA257–264 peptide. Cells were 
washed twice with ice-cold PBS and cell pellets were snap frozen in liquid nitrogen. 
Cells were lysed in 40 μ l 1% sodium deoxycholate, 40 mM chloroacetamide (both 
Sigma Aldrich), 10 mM TCEP (Thermo Scientific) and 100 mM Tris-HCl, pH 8 
(Life Technologies), boiled at 95° for 5 min and sonicated for 10 min in a Sonifier 
bath (Branson). An equal volume of 50 mM ammonium bicarbonate (Sigma 
Aldrich) was added, containing 600 ng Trypsin Gold (Promega). Samples were 
digested overnight at room temperature, acidified by addition of 1 μ l trifluoroacetic 
acid (Thermo Scientific) and loaded on in-house-prepared SDB-RPS StageTips 
(Empore). Peptides were desalted and eluted in three fractions by increasing 
concentrations of ammonium formate (100 mM and 150 mM) or 5% (v/v) 
ammonium hydroxide and acetonitrile (40%, 60% and 80% v/v)62. Sample volume 
was reduced by SpeedVac and supplemented with 2% acetonitrile, 0.1% TFA.
Mass spectrometry data acquisition. Tryptic peptides were separated by nanoscale 
C18 reverse chromatography coupled online to an Orbitrap Fusion Tribrid mass 
spectrometer via a NanoElectroSpray Ion Source (both Thermo Scientific). Peptides 
were loaded on a 20-cm 75–360 µ m inner-outer diameter fused silica emitter (New 
Objective) packed in-house with ReproSil-Pur C18-AQ 1.9-μ m  
resin (Dr Maisch GmbH). The column was installed on a Dionex Ultimate3000 RSLC 
NanoSystem (Thermo Scientific) using a MicroTee union formatted for 360 μ m  
outer diameter columns (IDEX) and a liquid junction. The spray voltage was set 
to 2.15 kV. Buffer A was composed of 0.5% acetic acid and buffer B of 0.5% acetic 
acid, 80% acetonitrile. Peptides were loaded for 17 min at 300 nl/min at 5% buffer 
B, equilibrated for 5 min at 5% buffer B (17–22 min) and eluted by increasing 
buffer B from 5 to 15% (22–87 min) and 15 to 38% (87–147 min), followed by a 
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10-min wash to 90% and a 5-min regeneration to 5%. Survey scans of peptide 
precursors from 400 to 1,500 m/z were performed at 120 K resolution (at 200 m/z) 
with a 1.5 × 105 ion count target. Tandem mass spectrometry was performed by 
isolation with the quadrupole with isolation window 1.6, HCD fragmentation with 
normalized collision energy of 30 and rapid scan mass spectrometry analysis in 
the ion trap. The MS2 ion count target was set to 104 and the maximum injection 
time was 35 ms. Only those precursors with charge states 2–7 were sampled for 
MS2. The dynamic exclusion duration was set to 60 s with a 10-p.p.m. tolerance 
around the selected precursor and its isotopes. Monoisotopic precursor selection 
was turned on. The instrument was run in top speed mode with 3-s cycles. All data 
were acquired with Xcalibur software.
Mass spectrometry data analysis. The RAW mass spectrometry files were 
processed with the MaxQuant computational platform, 1.5.0.25 (RNA pulldown) 
or 1.6.0.13 (memory OTI T cells)63. Proteins and peptides were identified using the 
Andromeda search engine by querying the human Uniprot database (downloaded 
February 2015, 89,796 entries) for the RNA pulldown, or the mouse Uniprot 
database (downloaded 18 August 2017, 51,434 entries) for analysis of memory OTI 
T cells. Standard settings with the additional options match between runs, label-
free quantification (LFQ), and unique peptides for quantification were selected. 
The generated ‘proteingroups.txt’ table was filtered for potential contaminants 
and reverse hits using Perseus 1.5.0.31 (RNA pulldown) or 1.5.1.6 (memory 
OTI T cells). The LFQ values were transformed in log2 scale, the triplicates per 
experimental condition grouped, and proteins filtered for at least three valid 
values in one of the experimental groups. Missing values were imputed by normal 
distribution (width = 0.3, shift = 1.8), assuming these proteins were close to the 
detection limit. To identify the proteins with the most prominent differences, we 
performed a two-sided t-test using an FDR of 5% and S0 of 0.4 (volcano plot). 
Mass spectrometry data of resting and activated memory T cells (Fig. 7 and 
Supplementary Fig. 7) are deposited at PRIDE: PXD008051.
mRNA expression analysis and ARE determination. mRNA expression of 
LCMV-specific spleen-derived central memory (CM) and effector memory (EM) 
T cells was extracted from Mackay et al.42 (GEO accession code GSE70813). Reads 
per million mapped reads (RPM) were transformed as log2-normalized counts 
using DESeq264.
To determine the presence of ARE sequences in mRNAs, the 3′ UTR sequences 
of all mouse transcripts were downloaded from Ensembl BioMart (release May 
2015) and compared to transcripts present in an RNA-seq dataset of memory  
T cells42. AREs (sequence motif ATTTA) were counted in all 3′ UTR variants. 
When multiple transcripts were present for a gene, we used the minimum, 
maximum and average count of AREs. Resulting data were combined with gene 
expression data by gene symbols.
Statistical analysis. Statistical analysis between groups was performed with 
GraphPad Prism 6, using the two-tailed Student t test when comparing two groups 
or one-way ANOVA test with Dunnett correction when comparing more than two 
groups. P values < 0.05 were considered statistically significant.
Reporting Summary. Further information on experimental design is available in 
the Nature Research Reporting Summary linked to this article.
Data and code availability. The materials, data, code and any associated protocols 
that support the findings of this study are available from the corresponding 
author upon reasonable request. The MS datasets have been deposited in the 
ProteomeXchange database under accession code PXD008051.
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    Experimental design
1.   Sample size
Describe how sample size was determined. For in vivo mouse experiments, sample size was determined for each experiment with the 
use of the guideline book of van Zutphen et al.: Proefdieren en dierproeven (translated: 
'experimental animals and animal experiments'), as required and approved by the 
Experimental Animal Committee. 
For in vitro experiments, the sample size was determined based on pilot experiments or 
previous studies. All experiments included at least 3 biological replicates and all 
experiments were performed at least twice. Data are compiled from independent 
experiments. 
Western blots are representative of three independently performed experiments. 
Each mass spectrometry experiment includes 3 biological replicates per group.
2.   Data exclusions
Describe any data exclusions. For the in vivo experiments all analyzed mice are included for analysis. 
For in vitro data, data exclusion was only applied when positive and/or negative controls of 
an experimental repeat demonstrated a failure of the experimental procedure.
3.   Replication
Describe the measures taken to verify the reproducibility 
of the experimental findings.
All data are reliably reproduced, and compiled from independent experiments in figures and 
statistical analysis as indicated in the figure legends.
4.   Randomization
Describe how samples/organisms/participants were 
allocated into experimental groups.
Randomization was not applicable in this study. 
In vivo studies required injection of naive T cells prior to Listeria OVA infection to follow 
responses. If possible, T cells with different features (WT and ARE-DEL) were co-injected to 
prevent effects by individual differences. Mice were always age and sex matched. 
For in vitro essays reporter constructs and other variations were tested in parallel in T cells 
from different individuals. All critical experiments were either performed independently by 
two researchers and yielded the same results, or they were performed by at least two 
researchers in a team.
5.   Blinding
Describe whether the investigators were blinded to 
group allocation during data collection and/or analysis.
Mass spectrometry samples were number coded prior to analysis. 
No further blinding was applied in this study, as internal controls were used in each 
experiment to obtain unbiased data.
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
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6.   Statistical parameters 
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the 
Methods section if additional space is needed). 
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same 
sample was measured repeatedly
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
Test values indicating whether an effect is present 
Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
   Software
Policy information about availability of computer code
7. Software
Describe the software used to analyze the data in this 
study. 
Flow Cytometry data analysis was performed using FlowJo software (Tree Star, version 7.6.5 
and version 10). 
Mass spectrometry data analysis was performed with the MaxQuant computational platform, 
1.5.0.25 (RNA pull down) or 1.6.0.13 (memory OTI T cells). The ‘proteingroups.txt’ table was 
filtered for potential contaminants and reverse hits using Perseus 1.5.0.31 (RNA pull down) or 
1.5.1.6 (memory OTI T cells).  
RNA seq data were reanalysed for Reads per million mapped reads (RPM) and transformed as 
log2-normalized counts using DESeq2. 
Statistical analysis between groups was performed with GraphPad Prism 6, using the 2-tailed 
Student t test when comparing 2 groups, or one-way ANOVA test with Dunnett correction 
when comparing > 2 groups. P values <0.05 were considered statistically significant.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made 
available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for 
providing algorithms and software for publication provides further information on this topic.
   Materials and reagents
Policy information about availability of materials
8.   Materials availability
Indicate whether there are restrictions on availability of 
unique materials or if these materials are only available 
for distribution by a third party.
No restrictions apply to the availability of materials.
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9.   Antibodies
Describe the antibodies used and how they were validated 
for use in the system under study (i.e. assay and species).
Flow Cytometry:  
Name / Clone name / Catalog no. / (most used) Lot no. / dilution factor / manufacturer 
 
Mouse cells were labeled with:  
anti-CD8 / 53-6.7 /  45-0081-82 / 4291993 / 1:400 / eBioscience 
anti-CD4 / GK1.5 / 48-0041-82 / 4289896 / 1:400 / eBioscience 
anti-CD45.1 / A20 / 110722 / B191340 / 1:400 / eBioscience 
anti-CD45.2 / 104 / 109808 / B155231 / 1:400 / eBioscience 
anti-Vβ5.1-5.2 / MR9-4 / 553189 / 66507 / 1:400 / BD Biosciences 
anti-CD44 / IM7 / 25-0441-82 / E07565-1632 / 1:400 / eBioscience 
anti-CD62L / MEL-14 / 104441 / B213054 / 1:400 / BioLegend 
anti-CD127 / A7R34 / 45-1271-82 / E08358-1631 / 1:200 / eBioscience 
anti-KLRG1 / MAFA (2F1) / 138416 / B196268 / 1:400 / BioLegend  
anti-IFN-γ / XMG1.2 / 17-7311-82 / 4332526 / 1:300 / eBioscience 
anti-TNF-α / MP6-XT22/ 12-7321-82 / E02144-1632 / 1:300 / eBioscience 
 
Human T cells were labeled with:  
anti-CD3 / UCHT1 / 737657 / 7973016 / 1:50 / Beckman Coulter 
anti-CD4 / SK3 / 345769 / 80868 / 1:50 / BD Biosciences 
anti-CD8 / SK1 / 345775 / 6229889 / 1:300 / BD Biosciences 
 
Dead cells were excluded with 1ng/ml TO-PRO-3 iodide (T3605, Sigma-Aldrich), or Near-IR 
(L10119, Life Technology / 1:800 dilution factor). 
 
Western blot: 
Name / Catalog no. / (most used) Lot no. / dilution factor / manufacturer 
 
Primary antibodies: 
rabbit anti-ZFP36L1 polyclonal antibody / ab42473 / GR33550-6 / 1:250 / Abcam 
rabbit anti-ZFP36L2 polyclonal antibody / ab70775 / GR93627-6 / 1:250 / Abcam 
mouse anti-RhoGDI monoclonal antibody / MAB9959 / 2017102001 / 1:1000 / Abnova 
mouse anti-GAPDH monoclonal antibody / MAB374 / 2842113 / 1:500 / Millipore 
rat pan-ZFP36 antibody / (M. Turner & J. McHugh unpublished data) / 1ug/ml  
 
Secondary antibodies: 
goat anti-rabbit-HRP / 4050-05 / 1:10000 / Southern Biotech 
goat anti-mouse-HRP / 1031-05 / 1:10000 / Southern Biotech 
goat anti-rat-HRP / 31470 / 1:10000 / Invitrogen 
 
The specificity of anti-ZFP36L1 polyclonal and pan-ZFP36 family monoclonal antibodies was 
assessed using transfected HEK 293T cells; the polyclonal antibody was also assessed using 
ZFP36/ZFP36L1 ko mice (M. Turner & J. McHugh unpublished data). The anti-ZFP36L2 
polyclonal antibody was verified by western blot analysis of ZFP36L2 ko T cells (see 
supplemental Fig 7D). 
RNA pull downs were validated with Western blot analysis. 
10. Eukaryotic cell lines
a.  State the source of each eukaryotic cell line used. For virus production, PlatE cells (Morita et al., Gene therapy 2000. 7:1063-1066), received 
from the lab for mouse and phoenix A cells for human T cells (ATCC® CRL-3213™) were used.
b.  Describe the method of cell line authentication used. Both cell lines yielded retrovirus and allowed for successful transduction of human and 
mouse T cells.
c.  Report whether the cell lines were tested for 
mycoplasma contamination.
Cell lines are regularly tested for mycoplasma and were negative for more than 8 years.
d.  If any of the cell lines used are listed in the database 
of commonly misidentified cell lines maintained by 
ICLAC, provide a scientific rationale for their use.
Cell lines are not listed
    Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
11. Description of research animals
Provide all relevant details on animals and/or 
animal-derived materials used in the study.
C57BL/6J, C57BL/6J.OT-I , C57BL/6J.OT-I IFN-g ARE-Del transgenic and Zfp36l2fl/fl CD4-cre 
were used when 6 to 12 weeks old. Both male and female mice were included in this study.
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Policy information about studies involving human research participants
12. Description of human research participants
Describe the covariate-relevant population 
characteristics of the human research participants.
Human T cells are derived from healthy blood donors that agreed to donate their blood to 
research. The donation is anonymous, so no information on sex/age is available.
